IconOVir Bio is a preclinical-stage biotechnology company that develops therapies to improve the treatment of patients with cancer. Its proprietary oncolytic virus platform is based designed to address key limitations of first- and second-generation oncolytic viruses. The company aims to produce tumor-selective oncolytic viruses that can be used in a wide variety of solid tumors, including metastatic disease.